Embattled TAVR Device Myval Meets Expectations in Trial, but Trouble Still Ahead

You May Be Interested In:Rep. Garcia of Long Beach asks RFK Jr. to explain targeting of HIV/AIDS funding for cuts



(MedPage Today) — For a balloon-expandable transcatheter aortic valve replacement (TAVR or TAVI) platform, the much-litigated Myval performed well enough in the COMPARE-TAVI 1 randomized trial, but its rates of pacemakers and paravalvular leaks…

share Paylaş facebook pinterest whatsapp x print

Similar Content

A computer rendering of neuronal inclusions in Huntington’s disease.
Brain Changes Emerge Decades Before Huntington’s Diagnosis
Expert Highlights Updates in Pediatric Vitiligo Care
Expert Highlights Updates in Pediatric Vitiligo Care
How to properly evaluate AI technologies? UVA Health analytics leader has answers
How to properly evaluate AI technologies? UVA Health analytics leader has answers
Allergy medications: Know your options
High potassium (hyperkalemia)
A photo of two asthma inhalers lying on a table.
One in Six Adults With Asthma Didn’t Adhere to Meds Due to Cost
Another House bill aims to protect against hospital cyberattacks
Another House bill aims to protect against hospital cyberattacks
The News Link | © 2025 | News